XTL Biopharmaceuticals Ltd
XTLB
Company Profile
Business description
XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commercialization of intellectual property. The Company is engaged in biotechnology through its subsidiary Psyga Bio and in the biopharmaceutical industry with hCDR1, a novel compound working via a novel mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE) and a potential treatment for Sjogren's syndrome (SS). It focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.
Contact
85 Medinat Hayehudim Street
Hertzlia4676670
ISRT: +972 542288897
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
This former ASX tech darling is now 25% undervalued
Shares have fallen over 40% this year but revenue is still growing quickly.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,291.30 | 23.50 | 0.25% |
| CAC 40 | 8,332.87 | 54.28 | 0.66% |
| DAX 40 | 26,662.77 | 315.32 | 1.20% |
| Dow JONES (US) | 52,400.94 | 169.05 | 0.32% |
| FTSE 100 | 10,835.47 | 83.88 | 0.78% |
| HKSE | 24,315.92 | 241.12 | -0.98% |
| NASDAQ | 25,609.15 | 543.28 | 2.17% |
| Nikkei 225 | 61,248.59 | 789.01 | 1.31% |
| NZX 50 Index | 14,179.86 | 12.45 | 0.09% |
| S&P 500 | 7,634.87 | 113.94 | 1.51% |
| S&P/ASX 200 | 9,153.20 | 24.20 | 0.27% |
| SSE Composite Index | 3,680.64 | 16.92 | 0.46% |